

ATTENTION ON ADHD: THE VALUE OF IMPROVING CARE FOR PEOPLE WITH ADHD SNAPSHOT



Canada

Overview of the ADHD Landscape in Canada

	ගිනී DISEASE BURDEN/EPIDEMIOLOGY	ADHD RESEARCH
Population 38,465,604 ¹	ADHD prevalence rate for adults (18-65) 2.5% ⁵ (577,220 patients) ⁶ **	Number of clinical trials 6 ⁷ (from 01.08.12 to 01.08.22)
Current health expenditure (% of GDP) 10.84% ²	REGISTRIES	PATIENT ORGANISATIONS
Domestic general government	Is there a ADHD registry in the country?	ADHD Canada CADDRA CADDAC
health expenditure (% of GDP) 18.58 ³		Ĩ NATIONAL GUIDELINES
Out-of-pocket expenditure (%) 14.914	Number of reference centres / centres of excellence	CADDRA guidelines

¹ World Population in Review. Canada Population (estimate on 31 August) Available at: <u>https://worldpopulationreview.com/countries/canada-population</u> Last accessed October 2022.

² The World Bank. Current Health expenditure (% of GDP) – Canada. Available at: <u>https://data.worldbank.org/indicator/SH.XPD.CHEX.GD.ZS?locations=CA</u> Last accessed October 2022.

³ The World Bank. Domestic general government health expenditure (% of GDP) - Canada. Available at: https://data.worldbank.org/indicator/SH.XPD.CHEX.GD.ZS?locations=CA Last accessed October 2022.

⁴ The World Bank. Out-of-pocket expenditure (% of current health expenditure) - Canada. Available at: https://data.worldbank.org/indicator/SH.XPD.OOPC.CH.ZS?locations=CA Last accessed October 2022.

⁵ Faraone S V., Banaschewski T, Coghill D, Zheng Y, Biederman J, Bellgrove MA, et al. The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder.

Neurosci Biobehav Rev. 2021 Sep 1;128:789-818.

⁶ Takeda provided regional-level statistics on the adult population (18-65)

⁷ Government of Canada Clinical Trials Database. Last accessed November 2022. Available at: <u>https://health-products.canada.ca/ctdb-bdec/index-eng.jsp</u>

*Treating to 70% of the estimated prevalence of patients means increasing rates of diagnosis meaning that the percentage of patients increases by 30% from 40-70 leading to a higher number of patients being treated in the health system). **Adult patient population is calculated by multiplying the ADHD prevalence rate from Faraone et al, 2021 by the country's 18-65 population data (see endnotes).

The Attention on ADHD site has been initiated and funded by Takeda. Copyright 2023 Takeda Pharmaceutical Company Limited. All rights reserved. Takeda and the Takeda Logo are registered trademarks of Takeda Pharmaceutical Company Limited.

Job number: C-ANPROM/EUC/ADH/0030